(Total Views: 292)
Posted On: 03/04/2020 11:18:45 AM
Post# of 36566
Good post, hoops. On another note, it’s AE’s earlier work on an II-key SARS vaccine that is very advantageous to their current project because it’s related. From a patent:
“Example 29
Ii-Key/SARS MHC Class II Epitope Hybrids
Prediction of Epitopes.
SARS coronavirusencodes two replicases, a spike protein, and a N protein and other proteins (genbank AY278488, AY278554, AY274119, AY278741). The 30 k virus genomes of different sources are highly homologous, indicating SARS coronavirus to be relatively stable. The “Beijing” coronavirus sequence AY278488 is taken as a prototypic model. One putative replicase (ORF-1), spike protein, and N protein have a high frequency of high-scoring HLA-DR-restricted epitopes upon examination with the Raghava program (access at: www.imtech.res.in/raghava/propred/). 40 SARS epitopes were identified and corresponding Ii-Key hybrids were synthesized.”
Ngio is a solid step ahead.
“Example 29
Ii-Key/SARS MHC Class II Epitope Hybrids
Prediction of Epitopes.
SARS coronavirusencodes two replicases, a spike protein, and a N protein and other proteins (genbank AY278488, AY278554, AY274119, AY278741). The 30 k virus genomes of different sources are highly homologous, indicating SARS coronavirus to be relatively stable. The “Beijing” coronavirus sequence AY278488 is taken as a prototypic model. One putative replicase (ORF-1), spike protein, and N protein have a high frequency of high-scoring HLA-DR-restricted epitopes upon examination with the Raghava program (access at: www.imtech.res.in/raghava/propred/). 40 SARS epitopes were identified and corresponding Ii-Key hybrids were synthesized.”
Ngio is a solid step ahead.
(2)
(0)
